Lexeo Therapeutics, Inc. (LXEO)Healthcare | Biotechnology | New York, United States | NasdaqGM
4.65 USD
-0.18
(-3.631%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:25 a.m. EDT
The investment case for Lexeo Therapeutics is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. The stock has lost nearly 75% of its value in the last year, a structural decline that reflects the market's verdict on the business quality rather than a temporary dislocation. Fundamentally, the company is burning cash aggressively with negative free cash flow and negative returns on equity, while holding minimal cash reserves against a backdrop of high debt relative to equity. The balance sheet is fragile, and there is no dividend to provide income or a floor. While analysts offer lofty price targets, these are disconnected from the reality of the company's financial bleed and the severe discount applied by the market. The options market confirms this pessimism, with traders buying deep protection rather than betting on a rally. Until the cash burn slows significantly and a credible path to profitability emerges, this remains a high-risk speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| MSTL_112 ✓ | 0.209961 |
| AutoTheta | 0.226392 |
| MSTL | 0.247427 |
| AutoARIMA | 0.251330 |
| AutoETS | 0.254309 |
Forecast horizon: 60 days | Selected: MSTL_112
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.618 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.181 |
| Market Cap | 364,732,992 |
| Forward P/E | -3.74 |
| Beta | 1.43 |
| Website | https://www.lexeotx.com |
As of July 11, 2026, 4:25 a.m. EDT: Speculators are positioning heavily for downside protection with significant open interest in out-of-the-money puts (strikes 4.0, 5.0, 6.0) across multiple expirations, while call volume is concentrated near the money or lower strikes. This imbalance suggests a dominant bearish sentiment and a fear of further decline rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.085585594 |
| Address1 | 345 Park Avenue South |
| Address2 | 6th Floor |
| All Time High | 22.33 |
| All Time Low | 1.45 |
| Ask | 5.88 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,064,340 |
| Average Daily Volume3 Month | 833,040 |
| Average Volume | 833,040 |
| Average Volume10Days | 1,064,340 |
| Beta | 1.427 |
| Bid | 3.41 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 3.125 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.645 |
| Current Ratio | 14.156 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.9 |
| Day Low | 4.54 |
| Debt To Equity | 3.181 |
| Display Name | Lexeo Therapeutics |
| Earnings Timestamp | 1,778,502,600 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda | -97,184,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.842 |
| Enterprise Value | 179,054,992 |
| Eps Current Year | -1.13857 |
| Eps Forward | -1.24333 |
| Eps Trailing Twelve Months | -1.12 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.0186 |
| Fifty Day Average Change | -0.3736 |
| Fifty Day Average Change Percent | -0.07444307 |
| Fifty Two Week Change Percent | 8.558559 |
| Fifty Two Week High | 10.99 |
| Fifty Two Week High Change | -6.345 |
| Fifty Two Week High Change Percent | -0.57734305 |
| Fifty Two Week Low | 3.6 |
| Fifty Two Week Low Change | 1.0450001 |
| Fifty Two Week Low Change Percent | 0.2902778 |
| Fifty Two Week Range | 3.6 - 10.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,699,018,200,000 |
| Float Shares | 47,278,661 |
| Forward Eps | -1.24333 |
| Forward P E | -3.735935 |
| Free Cashflow | -67,344,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -62,329,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00604 |
| Held Percent Institutions | 1.14635 |
| Implied Shares Outstanding | 78,521,634 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-11-03 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York. |
| Long Name | Lexeo Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 364,732,992 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_625814286 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -87,501,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 364,340,381 |
| Number Of Analyst Opinions | 9 |
| Open | 5.05 |
| Operating Cashflow | -97,989,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 212 547 9879 |
| Previous Close | 4.82 |
| Price Eps Current Year | -4.079679 |
| Price Hint | 4 |
| Price To Book | 1.4864 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.605 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.175 |
| Regular Market Change Percent | -3.63071 |
| Regular Market Day High | 4.9 |
| Regular Market Day Low | 4.54 |
| Regular Market Day Range | 4.54 - 4.9 |
| Regular Market Open | 5.05 |
| Regular Market Previous Close | 4.82 |
| Regular Market Price | 4.645 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 574,685 |
| Return On Assets | -0.32504 |
| Return On Equity | -0.54755 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 78,521,634 |
| Shares Percent Shares Out | 0.2054 |
| Shares Short | 16,129,164 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 13,775,211 |
| Short Name | Lexeo Therapeutics, Inc. |
| Short Percent Of Float | 0.24149999 |
| Short Ratio | 16.87 |
| Source Interval | 15 |
| State | NY |
| Symbol | LXEO |
| Target High Price | 30.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 20.88889 |
| Target Median Price | 20.0 |
| Total Cash | 193,043,008 |
| Total Cash Per Share | 2.458 |
| Total Debt | 7,365,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.11885 |
| Two Hundred Day Average Change | -2.4738503 |
| Two Hundred Day Average Change Percent | -0.347507 |
| Type Disp | Equity |
| Volume | 574,685 |
| Website | https://www.lexeotx.com |
| Zip | 10,010 |